Recursion to open office space within Mila and build machine learning team to focus on some of drug discovery's most challenging problems
"Recursion is executing at the forefront of multiple technical fields including biology, chemistry, automation, engineering and data science," said Recursion Co-Founder and CEO
Recursion will open office space within Mila and build a team focused on using machine learning for tech-enabled drug discovery. The Montreal office will collaborate with the company's first major multidisciplinary expansion in
"Mila and
Recursion leverages machine learning to unravel complex patterns of biology within its more than 8 PB and growing proprietary biological datasets generated in-house at the company's headquarters in
"We are thrilled to welcome Recursion to Mila's campus. By leveraging machine learning for drug discovery, the combined efforts of Mila and Recursion have the potential to scale up and ramp up the search for drug candidate molecules," said
Learn more about Recursion and view open positions at Recursion.com/Careers.
About Recursion
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering. Our goal is to radically improve the lives of patients and industrialize drug discovery. Central to our mission is the Recursion Operating System, which combines an advanced infrastructure layer to generate what we believe is one of the world's largest and fastest-growing proprietary biological and chemical datasets. We combine that with the Recursion Map, a suite of custom software, algorithms and machine learning tools that we use to explore foundational biology unconstrained by human bias and navigate to new biological insights. Learn more at www.recursion.com, or connect on Twitter and LinkedIn.
About Mila
Founded by Professor
Press Contact
Elyse.Freeman@Recursion.com
Investor Relations Contact
InvestorRelations@Recursion.com
Forward-Looking Statements
This press release contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements provide our expectations or forecasts regarding future events. You can identify these statements by the fact they do not relate strictly to historical or current facts. They may use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, forward-looking statements include statements relating to intended future actions; plans with respect to clinical trials and preclinical activities; prospective products or product approvals; future performance or results of anticipated products or technology; expenses; our ability to obtain, maintain and enforce intellectual property protections and financial results; in addition to other topics. Any or all of our forward-looking statements here or elsewhere may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements and from expected or historical results. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. In particular, you should read the discussion in the "Risk Factors" section in our Prospectus filed with the
View original content to download multimedia:http://www.prnewswire.com/news-releases/recursion-announces-multi-year-collaboration-with-mila-for-tech-enabled-drug-discovery-301318007.html
SOURCE Recursion
© Canada Newswire, source